drugset / Trial / NCT05013216
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Phase 1
Recruiting
37 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collabStand Up To Cancer · collab
Non-randomizedSequentialOpen-labelPrevention
Summary
This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant for patients who have been identified to be at risk of developing pancreatic cancer.
Timeline
- Start
- 2022-04-11
- Primary completion
- 2027-10-01
- Completion
- 2031-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KRAS peptide vaccine | Vaccine | 1.8 mg | — |
| Background | Hiltonol | Other / unclassified | 0.5 mg | — |